These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
203 related items for PubMed ID: 12134305
1. [Nicotinic Receptor, galantamine and Alzheimer disease]. Arroyo G, Aldea M, Fuentealba J, García AG. Rev Neurol; ; 34(11):1057-65. PubMed ID: 12134305 [Abstract] [Full Text] [Related]
4. [Galantamine: a novel cholinergic agent for Alzheimer's disease]. Olazarán J, García G. Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973 [Abstract] [Full Text] [Related]
5. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R. Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb 01; 34(1):104-10. PubMed ID: 19833161 [Abstract] [Full Text] [Related]
6. [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences]. Nieoullon A. Psychol Neuropsychiatr Vieil; 2010 Jun 01; 8(2):123-31. PubMed ID: 20525543 [Abstract] [Full Text] [Related]
7. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Drugs Aging; 2004 Jun 01; 21(7):453-78. PubMed ID: 15132713 [Abstract] [Full Text] [Related]
8. Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Galvin JE, Cornblatt B, Newhouse P, Ancoli-Israel S, Wesnes K, Williamson D, Zhu Y, Sorra K, Amatniek J. Alzheimer Dis Assoc Disord; 2008 Jun 01; 22(1):30-8. PubMed ID: 18317244 [Abstract] [Full Text] [Related]
9. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. Geerts H, Grossberg GT. J Clin Pharmacol; 2006 Jul 01; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810 [Abstract] [Full Text] [Related]
10. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). Maelicke A. Int J Clin Pract Suppl; 2001 May 01; (120):24-8. PubMed ID: 11406923 [Abstract] [Full Text] [Related]
11. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens. Caricati-Neto A, D'angelo LC, Reuter H, Hyppolito Jurkiewicz N, Garcia AG, Jurkiewicz A. Eur J Pharmacol; 2004 Oct 25; 503(1-3):191-201. PubMed ID: 15496314 [Abstract] [Full Text] [Related]
12. An update on the pharmacology of galantamine. Villarroya M, García AG, Marco-Contelles J, López MG. Expert Opin Investig Drugs; 2007 Dec 25; 16(12):1987-98. PubMed ID: 18042006 [Abstract] [Full Text] [Related]
13. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Emre M. Int J Clin Pract Suppl; 2002 Jun 25; (127):64-72. PubMed ID: 12139369 [Abstract] [Full Text] [Related]
14. Galantamine: use in Alzheimer's disease and related disorders. Bullock R. Expert Rev Neurother; 2004 Mar 25; 4(2):153-63. PubMed ID: 15853556 [Abstract] [Full Text] [Related]
15. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Aguglia E, Onor ML, Saina M, Maso E. Curr Med Res Opin; 2004 Nov 25; 20(11):1747-52. PubMed ID: 15537474 [Abstract] [Full Text] [Related]
16. Nicotinic cholinergic modulation: galantamine as a prototype. Woodruff-Pak DS, Lander C, Geerts H. CNS Drug Rev; 2002 Nov 25; 8(4):405-26. PubMed ID: 12481195 [Abstract] [Full Text] [Related]
17. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Dajas-Bailador FA, Heimala K, Wonnacott S. Mol Pharmacol; 2003 Nov 25; 64(5):1217-26. PubMed ID: 14573772 [Abstract] [Full Text] [Related]
18. In vitro galantamine-memantine co-application: mechanism of beneficial action. Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T. Neuropharmacology; 2006 Dec 25; 51(7-8):1181-91. PubMed ID: 17011596 [Abstract] [Full Text] [Related]
19. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes K, Hammond G, Schwalen S, GAL-INT-28 Study Group. Curr Med Res Opin; 2005 Sep 25; 21(9):1423-9. PubMed ID: 16197661 [Abstract] [Full Text] [Related]
20. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lübbert H, Albuquerque EX, Maelicke A. J Pharmacol Exp Ther; 2003 Jun 25; 305(3):1024-36. PubMed ID: 12649296 [Abstract] [Full Text] [Related] Page: [Next] [New Search]